BR112017012647A2 - composição imunogênica, método para proteção contra ou prevenção de herpes zoster (hz) e/ou neuralgia pós-herpética, e, método para proteção contra, prevenção ou redução da incidência de herpes zoster e/ou neuralgia pós-herpética. - Google Patents

composição imunogênica, método para proteção contra ou prevenção de herpes zoster (hz) e/ou neuralgia pós-herpética, e, método para proteção contra, prevenção ou redução da incidência de herpes zoster e/ou neuralgia pós-herpética.

Info

Publication number
BR112017012647A2
BR112017012647A2 BR112017012647A BR112017012647A BR112017012647A2 BR 112017012647 A2 BR112017012647 A2 BR 112017012647A2 BR 112017012647 A BR112017012647 A BR 112017012647A BR 112017012647 A BR112017012647 A BR 112017012647A BR 112017012647 A2 BR112017012647 A2 BR 112017012647A2
Authority
BR
Brazil
Prior art keywords
prevention
protection against
herpes zoster
postherpetic neuralgia
incidence
Prior art date
Application number
BR112017012647A
Other languages
English (en)
Portuguese (pt)
Inventor
Guy Christian Ledent Edouard
Pierre Fernand Lecrenier Nicolas
Charles Heineman Thomas
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201503266A external-priority patent/GB201503266D0/en
Priority claimed from GBGB1518917.8A external-priority patent/GB201518917D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112017012647A2 publication Critical patent/BR112017012647A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR112017012647A 2014-12-18 2015-12-16 composição imunogênica, método para proteção contra ou prevenção de herpes zoster (hz) e/ou neuralgia pós-herpética, e, método para proteção contra, prevenção ou redução da incidência de herpes zoster e/ou neuralgia pós-herpética. BR112017012647A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB201422686 2014-12-18
GB201503266A GB201503266D0 (en) 2015-02-26 2015-02-26 Vaccination
GBGB1518917.8A GB201518917D0 (en) 2015-10-26 2015-10-26 Vaccination
PCT/EP2015/079967 WO2016096968A1 (en) 2014-12-18 2015-12-16 Vaccination

Publications (1)

Publication Number Publication Date
BR112017012647A2 true BR112017012647A2 (pt) 2018-01-09

Family

ID=54937057

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012647A BR112017012647A2 (pt) 2014-12-18 2015-12-16 composição imunogênica, método para proteção contra ou prevenção de herpes zoster (hz) e/ou neuralgia pós-herpética, e, método para proteção contra, prevenção ou redução da incidência de herpes zoster e/ou neuralgia pós-herpética.

Country Status (8)

Country Link
US (1) US20180008700A1 (enrdf_load_stackoverflow)
EP (1) EP3233118A1 (enrdf_load_stackoverflow)
JP (1) JP2018500322A (enrdf_load_stackoverflow)
CN (1) CN107106675A (enrdf_load_stackoverflow)
BR (1) BR112017012647A2 (enrdf_load_stackoverflow)
CA (1) CA2970840A1 (enrdf_load_stackoverflow)
MX (1) MX2017008055A (enrdf_load_stackoverflow)
WO (1) WO2016096968A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016342371B2 (en) * 2015-10-22 2023-05-11 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (VZV)
CA3003483C (en) 2015-11-06 2022-09-13 Adjuvance Technologies, Inc. Triterpene saponin analogues
WO2018198085A1 (en) 2017-04-28 2018-11-01 Glaxosmithkline Biologicals Sa Vaccination
MY195490A (en) * 2018-05-23 2023-01-26 Mogam Inst Biomedical Res Antigen Variant Of Varicella Zoster Virus And Use Thereof
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
WO2021091997A1 (en) * 2019-11-05 2021-05-14 Adjuvance Technologies, Inc. Varicella zoster
EP4526327A1 (en) * 2022-05-20 2025-03-26 GlaxoSmithKline Biologicals S.A. Modified varicella zoster virus glycoprotein e proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物

Also Published As

Publication number Publication date
CA2970840A1 (en) 2016-06-23
JP2018500322A (ja) 2018-01-11
CN107106675A (zh) 2017-08-29
MX2017008055A (es) 2017-09-28
US20180008700A1 (en) 2018-01-11
WO2016096968A1 (en) 2016-06-23
EP3233118A1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
BR112017012647A2 (pt) composição imunogênica, método para proteção contra ou prevenção de herpes zoster (hz) e/ou neuralgia pós-herpética, e, método para proteção contra, prevenção ou redução da incidência de herpes zoster e/ou neuralgia pós-herpética.
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
PH12016501668A1 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
BR112018077266A2 (pt) composições compreendendo cepas bacterianas
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
DOP2017000268A (es) Metodos y kits para tratar depresion
BR112017008284A8 (pt) Bifidobactérias ativadas e métodos para uso das mesmas
BR112014017716A8 (pt) composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol
UY36703A (es) Composiciones y métodos para la administración de un polinucleótido en una planta
BR112016023851A2 (pt) ?composição de revestimento de duas partes e método para revestir uma superfície?
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
BR112017022089A2 (pt) uso de uma composição, e, método para branqueamento de dentes
BR112014031112A2 (pt) nanossistemas para formulação de biocidas eficazes de risco mínimo
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
MX2017004828A (es) Composicion oftalmica que comprende ciclosporina y trehalosa.
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
BR112017000199A2 (pt) composição adjuvante que compreende cloreto de colina ou fosfato de potássio (dibásico como um inibidor de hidratação)
MX2017002803A (es) Coronavirus bovino atenuado y vacunas relacionadas.
EP3519427A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
MX2016007356A (es) Composicion para administracion oral de agentes bioactivos.
ZA201802606B (en) Compositions for dental varnishes and methods of making and using same
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]